| Attribute |
Value |
| 52 Week Change |
0.38853765 |
| Address1 |
One Amgen Center Drive |
| All Time High |
447.03 |
| All Time Low |
0.075521 |
| Ask |
432.1 |
| Ask Size |
2 |
| Audit Risk |
7 |
| Average Analyst Rating |
2.6 - Hold |
| Average Daily Volume10 Day |
2,548,780 |
| Average Daily Volume3 Month |
2,755,428 |
| Average Volume |
2,755,428 |
| Average Volume10Days |
2,548,780 |
| Beta |
0.407 |
| Bid |
408.2 |
| Bid Size |
1 |
| Board Risk |
8 |
| Book Value |
21.62 |
| City |
Thousand Oaks |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
2 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
412.84 |
| Current Ratio |
1.371 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
420.35 |
| Day Low |
411.04 |
| Debt To Equity |
490.281 |
| Display Name |
Amgen |
| Dividend Date |
1,789,084,800 |
| Dividend Yield |
2.44 |
| Earnings Call Timestamp End |
1,793,736,000 |
| Earnings Call Timestamp Start |
1,793,736,000 |
| Earnings Growth |
0.649 |
| Earnings Quarterly Growth |
0.659 |
| Earnings Timestamp |
1,793,736,000 |
| Earnings Timestamp End |
1,793,736,000 |
| Earnings Timestamp Start |
1,793,736,000 |
| Ebitda |
17,268,000,768 |
| Ebitda Margins |
0.45329 |
| Enterprise To Ebitda |
15.434 |
| Enterprise To Revenue |
6.996 |
| Enterprise Value |
266,509,516,800 |
| Eps Current Year |
23.0222 |
| Eps Forward |
24.51066 |
| Eps Trailing Twelve Months |
16.1 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,787,270,400 |
| Exchange |
NMS |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fax |
805 447 1010 |
| Fifty Day Average |
413.2156 |
| Fifty Day Average Change |
-0.37561035 |
| Fifty Day Average Change Percent |
-0.00090899365 |
| Fifty Two Week Change Percent |
38.853764 |
| Fifty Two Week High |
447.03 |
| Fifty Two Week High Change |
-34.190002 |
| Fifty Two Week High Change Percent |
-0.07648257 |
| Fifty Two Week Low |
288.0 |
| Fifty Two Week Low Change |
124.84 |
| Fifty Two Week Low Change Percent |
0.43347222 |
| Fifty Two Week Range |
288.0 - 447.03 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
424,704,600,000 |
| Five Year Avg Dividend Yield |
3.0 |
| Float Shares |
539,156,080 |
| Forward Eps |
24.51066 |
| Forward P E |
16.843283 |
| Free Cashflow |
8,645,624,832 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
31,500 |
| Fullday Change |
-4.730011 |
| Fullday Change Percent |
-1.1327468 |
| Fullday Price |
412.84 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,790,812,800 |
| Gross Margins |
0.71891 |
| Gross Profits |
27,387,000,832 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.00228 |
| Held Percent Institutions |
0.84989 |
| Implied Shares Outstanding |
540,632,005 |
| Industry |
Drug Manufacturers - General |
| Industry Disp |
Drug Manufacturers - General |
| Industry Key |
drug-manufacturers-general |
| Ir Website |
http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-IRHome |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Dividend Date |
1,787,270,400 |
| Last Dividend Value |
2.52 |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
943,228,800 |
| Last Split Factor |
2:1 |
| Long Business Summary |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California. |
| Long Name |
Amgen Inc. |
| Market |
us_market |
| Market Cap |
223,194,513,408 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_24816 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
8,743,000,064 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
219,545,250,910 |
| Number Of Analyst Opinions |
29 |
| Open |
420.35 |
| Operating Cashflow |
12,478,000,128 |
| Operating Margins |
0.35548002 |
| Overall Risk |
3 |
| Payout Ratio |
0.6087 |
| Peg Ratio |
2.52 |
| Phone |
805 447 1000 |
| Previous Close |
417.57 |
| Price Eps Current Year |
17.932257 |
| Price Hint |
2 |
| Price To Book |
19.095282 |
| Price To Sales Trailing12 Months |
5.8588924 |
| Profit Margins |
0.22951001 |
| Quick Ratio |
0.95 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
hold |
| Recommendation Mean |
2.64706 |
| Region |
US |
| Regular Market Change |
-4.73001 |
| Regular Market Change Percent |
-1.13275 |
| Regular Market Day High |
420.35 |
| Regular Market Day Low |
411.04 |
| Regular Market Day Range |
411.04 - 420.35 |
| Regular Market Open |
420.35 |
| Regular Market Previous Close |
417.57 |
| Regular Market Price |
412.84 |
| Regular Market Time |
1,791,921,601 |
| Regular Market Volume |
2,319,532 |
| Return On Assets |
0.08667 |
| Return On Equity |
0.91473 |
| Revenue Growth |
0.095 |
| Revenue Per Share |
70.677 |
| Sand P52 Week Change |
0.17004645 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
2 |
| Shares Outstanding |
540,632,005 |
| Shares Percent Shares Out |
0.025899999 |
| Shares Short |
14,028,739 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
12,973,938 |
| Short Name |
Amgen Inc. |
| Short Percent Of Float |
0.025999999 |
| Short Ratio |
4.45 |
| Source Interval |
15 |
| State |
CA |
| Symbol |
AMGN |
| Target High Price |
500.0 |
| Target Low Price |
225.0 |
| Target Mean Price |
394.7714 |
| Target Median Price |
405.0 |
| Total Cash |
13,989,000,192 |
| Total Cash Per Share |
25.875 |
| Total Debt |
57,303,998,464 |
| Total Revenue |
38,094,999,552 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
9.8 |
| Trailing Annual Dividend Yield |
0.023469118 |
| Trailing Eps |
16.1 |
| Trailing P E |
25.642235 |
| Trailing Peg Ratio |
2.4515 |
| Triggerable |
1 |
| Two Hundred Day Average |
367.3929 |
| Two Hundred Day Average Change |
45.447083 |
| Two Hundred Day Average Change Percent |
0.12370158 |
| Type Disp |
Equity |
| Volume |
2,319,532 |
| Website |
https://www.amgen.com |
| Zip |
91,320-1799 |